6/3
08:01 am
mynz
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Medium
Report
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
5/31
05:01 pm
mynz
Mainz Biomed Reports Results of 2024 Annual General Meeting
Low
Report
Mainz Biomed Reports Results of 2024 Annual General Meeting
5/28
08:01 am
mynz
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
High
Report
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
5/20
08:01 am
mynz
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
Medium
Report
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
5/7
08:01 am
mynz
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
Low
Report
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
4/25
09:29 am
mynz
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
Medium
Report
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
4/12
10:08 am
mynz
Mainz Biomed (NASDAQ: MYNZ) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Mainz Biomed (NASDAQ: MYNZ) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
4/9
08:01 am
mynz
Mainz Biomed Reports Full Year 2023 Financial Results
Medium
Report
Mainz Biomed Reports Full Year 2023 Financial Results